MRK•benzinga•
The European Commission Has Approved Merck's Capvaxive (Pneumococcal 21-valent Conjugate Vaccine) For Active Immunization For The Prevention Of Invasive Disease And Pneumonia Caused By Streptococcus Pneumoniae Serotypes In Individuals 18 Years Of Age And
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on March 26, 2025 by benzinga